T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities

Blood

Volumn 95, Issue 12, 2000, Pages 3996-4003

  Champlin, Richard E ^b   Passweg, Jakob R ^c   Zhang, Mei Jie ^a   Rowlings, Philip A ^a   Pelz, Corey J ^a   Atkinson, Kerry A ^d   Barrett, A John ^e   Cahn, Jean Yves ^f   Drobyski, William R ^a   Gale, Robert Peter ^g   Goldman, John M ^h   Gratwohl, Alois ^c   Gordon Smith, Edward C ⁱ   Henslee Downey, P Jean ^j   Herzig, Roger H ^k   Klein, John P ^a   Marmont, Alberto M ^l   O'Reilly, Richard J ^m   Ringdén, Olle ⁿ   Slavin, Shimon ^o   Sobocinski, Kathleen A ^a   Speck, Bruno ^c   Weiner, Roy S ^p   Horowitz, Mary M ^a   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Coulter Cellular Therapies ^*  (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^g Ctr for Adv Studies in Leukemia   (United States)

^h Royal Postgraduate Medical School   (United States)

ⁱ ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^j UNIVERSITY OF SOUTH CAROLINA   (United States)

^k UNIVERSITY OF LOUISVILLE   (United States)

^l UNIVERSITY OF GENOA   (Italy)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^p TULANE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; T LYMPHOCYTE ANTIBODY;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BONE MARROW TRANSPLANTATION; DONOR; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECIPIENT; T LYMPHOCYTE;

EID: 18844467941     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667.
2. Gratwohl A, Hermans J, Apperley J, et al, for the Working Party on Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Blood. 1995;86:813.
3. Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am. 1990;4:687.
4. O'Reilly RJ. T-cell depletion and allogeneic bone marrow transplantation. Semin Hematol. 1992; 29(suppl 1):20.
5. Martin PJ, Hansen JA, Buckner D, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 1985;66:664.
6. Prentice HG, Blacklock HA, Janossy G, et al. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet. 1982;1:700.
7. Waldmann H, Polliak A, Hale G, et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet. 1984;2:483.
8. Antin JH, Bierer BE, Smith BR, et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood. 1991;78: 2139.
9. De Witte T, Hoogenhout J, de Pauw B, et al. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation. Blood. 1986;67:1302.
10. Maraninchi D, Mawas C, Guyotat D, et al. Selective depletion of marrow-T cytotoxic lymphocytes (CD8) in the prevention of graft-versus-host disease after allogeneic bone-marrow transplantation. Transplant Int. 1988;1:91.
11. Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992;10:1191.
12. Filipovich AH, Vallera D, McGlave P, et al. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation: the correlation between residual CD5 negative T cells and subsequent graft-versus-host disease. Transplantation. 1990;50:410.
13. Wagner JE, Santos GW, Noga SJ, et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood. 1990;75:1370.
14. Herve P, Flesch M, Cahn JY, et al. Removal of marrow T cells with OKT3-OKT11 monoclonal antibodies and complement to prevent acute graft-versus-host disease: a pilot study in ten patients. Transplantation. 1985;39:138.
15. Slocombe GW, Newland AC, Yeatman NWJ, Macey M, Jones HM, Knott L. Allogeneic bone marrow transplantation for adult leukaemia with soy bean lectin fractionated marrow. Bone Marrow Transplant. 1986;1:31.
16. Jansen J, Hanks S, Akard L, et al. Selective T cell depletion with CD8-conjugated magnetic beads in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15:271.
17. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplant in leukemia. Blood. 1991;78:2120.
18. Mitsuyasu RT, Champlin RE, Gate RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease: a prospective, randomized, double-blind trial. Ann Intern Med. 1986;105:20.
19. Ringdén O, Remberger M, Aschan J, Ljungman P, Lonnqvist B, Markling L. Long-term follow-up of a randomized trial comparing T cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients. Transplantation. 1994;58:887.
20. Atkinson K, Biggs J, Cooley M, et al. A comparative study of T-cell depleted and non-depleted marrow transplantation for hematological malignancy. Aust N Z J Med. 1987;17:16.
21. Racadot E, Herve P, Beaujean F, et al. Prevention of graft-versus-host disease in HLA-matched bone marrow transplantation for malignant diseases: a multicentric study of 62 patients using 3-pan-T monoclonal antibodies and rabbit complement. J Clin Oncol. 1987;5:426.
22. Bunjes D, Hertenstein B, Wiesneth M, et al. In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate. Bone Marrow Transplant. 1995;15:563.
23. Marks DI, Hughes TP, Szydlo R, et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in the first chronic phase: influence of GVHD prophylaxis on outcome. Br J Haematol. 1992;81:383.
24. Apperley JF, Jones L, Hale G, et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1986;1:53.
25. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987;2:175.
26. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806.
27. Ochs L, Shu OX, Miller J, et al. Late infections after allogeneic bone marrow transplantation Comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86:3979.
28. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593.
29. Cavazzana-Calvo M, Bordigoni P, Michel G, et al. A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Br J Haematol. 1996;93:131.
30. Ringdén O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood. 1993;81:1094.
31. Horowitz MM, Bortin MM. The role of registries in evaluating the results of bone marrow transplantation. In: Treleaven J, Barren J, eds. Bone Marrow Transplantation in Practice. Edinburgh: Churchill Livingstone; 1992:367.
32. Clift RA, Goldman J, Gratwohl A, Horowitz M. Proposals for standardized reporting of results of bone marrow transplantation for leukemia. Bone Marrow Transplant. 1989;4:445.
33. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73:606.
34. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295.
35. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987;67:397.
36. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75:2459.
37. Cox DR. Regression models and life-tables. J R Stat Soc (B). 1972;34:187.
38. Andersen PK, Borgan O, Gill R, Keiding N. Statistical Models Based on Counting Processes. New York: Springer-Verlag; 1992.
39. Klein JP Moeschberger ML. Survival Analysis: Techniques of Censored and Truncated Data. New York: Springer-Verlag; 1996.
40. Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994; 83:1980.
41. Ash RC, Horowitz MM, Gale RP, et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant. 1991;7:443.
42. Ash RC, Casper JT, Chitambar CR, et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med. 1990;322:485.
43. Quinones RR, Gutierrez RH, Dinndorf PA, et al. Extended-cycle elutriation to adjust T-cell content in HLA-disparate bone marrow transplantation. Blood. 1993;82:307.
44. Henslee-Downey PJ, Parrish RS, MacDonald JS, et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation. 1996;61:738.
45. Fleming DR, Henslee-Downey PJ, Romond EH, et al. Allogeneic bone marrow transplantation with T-cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study. Bone Marrow Transplant. 1996; 17:917.
46. Spencer A, Szydlo RM, Brookes PA, et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood. 1995;86:3590.
47. Bradley BA, Hows JM, Gore SM, et al. Current status of unrelated-donor bone marrow transplantation: the International Marrow Unrelated Search and Transplant (IMUST) Study. Clin Transplants. 1992;91.
48. Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood. 1995;85: 3302.
49. Naparstek E, Or R, Nagler A, et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol. 1995;89:506.
50. Verdonck LF, Dekker AW, de Gast GC, van Kempen ML, Lokhorst HM, Nieuwenhuis HK. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood. 1994;83:3090.
51. Clark RE, Pender N. Transplantation of T-lymphocyte depleted marrow with an addback of T cells. Hematol Oncol. 1995;13:219.
52. Champlin R, Giralt S, Przepiorka D, et al. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus-leukemia. Prog Clin Biol Res. 1992;377:385.
53. Dreger P, Viehmann K, Steinmann J, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. Exp Hematol. 1995;23:147.
54. Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. Clin Transpl. 1996;24:281.
55. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical 'three loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte-colony-stimulating factor mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84:3948.
56. Kaufman CL, Colson YL, Wren SM Watkins S, Simmons RL, Ildstad ST. Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood. 1994;84:2436.
57. Henslee-Downey PJ, Abhjyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997;89:3864.